article thumbnail

FDA Makes Low-Risk Determination for Marketing of Products from Genome-Edited Beef Cattle After Safety Review

The Pharma Data

Food and Drug Administration announced it has made a low-risk determination for the marketing of products, including food, from two genome-edited beef cattle and their offspring after determining that the intentional genomic alteration (IGA) does not raise any safety concerns (low-risk determination). The FDA, an agency within the U.S.

Genome 52
article thumbnail

Evolution in Hepatitis B and C Virus: Can we expect success similar to Hepatitis C in Hepatitis B as well?

Delveinsight

Hepatitis C treatment options, without a doubt, have improved significantly, including pan-genotypic medications that are used to treat all genotypes and subtypes. Typically, pan-genotypic treatments have high cure rates, few side effects, and short treatment durations (usually 8–12 weeks). and GT2 and GT3 with ribavirin.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

LabCorp Backs Resolution Bioscience’s Liquid Biopsy Test for NSCLC

XTalks

Moreover, the test will also allow clinicians to monitor the evolution of a patient’s tumor genotype during the course of therapy through serial and almost real-time assessments; this will help to better guide treatment decisions and care. In the US, Medicare covers the test.

Gene 105
article thumbnail

Nutrigenomics: The Future of Personalized Nutrition

Roots Analysis

Recent advances in DNA sequencing technologies have led to significant developments in healthcare-focused research on precision medicine and diagnostics. Nutritional DNA testing helps in identifying foods that might lead to allergies or intolerance in an individual.

Genome 40